Hansa Biopharma AB (OSTO:HNSA)
kr 45.9 -2.6 (-5.36%) Market Cap: 3.00 Bil Enterprise Value: 3.41 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Hansa Biopharma AB at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / NTS GMT
Release Date Price: kr117.1 (-3.06%)
Unidentified Analyst

Good afternoon, everyone, and thank you for coming to the 2020 Virtual UBS Global Health Care Conference. My name is [Tay], and I'm happy to be your host for this session. Our next presenter will be Søren Tulstrup, President and CEO of Hansa Biopharma. Following the presentation, we will have a Q&A session. (Operator Instructions) As a reminder, all presentations will be limited to 40 minutes, including Q&A.

We now turn it over to Soren. Thank you.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you, moderator, and good morning or good afternoon, everyone, and thank you for your interest in Hansa Biopharma.

Please turn to Slide 2. Before I start, I just want to point to the fact that this presentation contains forward-looking statements. And as such, you should apply the usual caution.

Now please turn to Slide 3, a high-level overview of Hansa Biopharma. So Hansa Biopharma was founded back in 2007 as a spinout from Lund

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot